Augmented Renal Clearance in Pediatric Intensive Care: Are We Undertreating Our Sickest Patients?
Overview
Pediatrics
Authors
Affiliations
Many critically ill patients display a supraphysiological renal function with enhanced renal perfusion and glomerular hyperfiltration. This phenomenon described as augmented renal clearance (ARC) may result in enhanced drug elimination through renal excretion mechanisms. Augmented renal clearance seems to be triggered by systemic inflammation and therapeutic interventions in intensive care. There is growing evidence that ARC is not restricted to the adult intensive care population, but is also prevalent in critically ill children. Augmented renal clearance is often overlooked due to the lack of reliable methods to assess renal function in critically ill children. Standard equations to calculate glomerular filtration rate (GFR) are developed for patients who have a steady-state creatinine production and a stable renal function. Those formulas are not reliable in critically ill patients with acutely changing GFR and tend to underestimate true GFR in patients with ARC. Tools for real-time, continuous, and non-invasive measurement of fluctuating GFR are most needed to identify changes in kidney function during critical illness and therapeutic interventions. Such devices are currently being validated and hold a strong potential to become the standard of practice. In the meantime, urinary creatinine clearance is considered the most reliable method to detect ARC in critically ill patients. Augmented renal clearance is clearly associated with subtherapeutic antimicrobial concentrations and subsequent therapeutic failure. This warrants the need for adjusted dosing regimens to optimize pharmacokinetic and pharmacodynamic target attainment. This review aims to summarize current knowledge on ARC in critically ill children, to give insight into its possible pathophysiological mechanism, to evaluate screening methods for ARC in the pediatric intensive care population, and to illustrate the effect of ARC on drug exposure, therapeutic efficacy, and clinical outcome.
Population pharmacokinetics and dose optimization of ceftazidime in critically ill children.
Li M, Gao L, Wang Z, Zeng L, Chen C, Wang J Front Pharmacol. 2024; 15:1470350.
PMID: 39664522 PMC: 11631598. DOI: 10.3389/fphar.2024.1470350.
Alshouli B, Abbas M, Alsharji R, Jaber A PLoS One. 2024; 19(9):e0310081.
PMID: 39298392 PMC: 11412532. DOI: 10.1371/journal.pone.0310081.
Gebreyesus M, Dresner A, Wiesner L, Coetzee E, Verschuuren T, Wasmann R CPT Pharmacometrics Syst Pharmacol. 2024; 13(9):1595-1605.
PMID: 38962872 PMC: 11881764. DOI: 10.1002/psp4.13196.
Dhont E, Van Der Heggen T, Snauwaert E, Willems J, Croubels S, Delanghe J Pediatr Nephrol. 2023; 39(5):1607-1616.
PMID: 37994980 DOI: 10.1007/s00467-023-06221-4.
Wong Vega M, Starr M, Brophy P, Devarajan P, Soranno D, Akcan-Arikan A Pediatr Nephrol. 2023; 39(3):981-992.
PMID: 37878137 PMC: 10817838. DOI: 10.1007/s00467-023-06178-4.